These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36425872)

  • 1. Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up.
    Fluhrer H; Hutterer GC; Golbeck S; Stidl M; Niedrist T; Pichler R; Mischinger J; Seles M; Mannweiler S; Spiegelberg J; Bauernhofer T; Jost PJ; Ahyai S; Zigeuner R; Pichler M; Barth DA
    Ther Adv Med Oncol; 2022; 14():17588359221134065. PubMed ID: 36425872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
    Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
    Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
    de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
    Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy.
    Meagher MF; Minervini A; Mir MC; Cerrato C; Rebez G; Autorino R; Hampton L; Campi R; Kriegmair M; Linares E; Hevia V; Musquera M; D'Anna M; Roussel E; Albersen M; Pavan N; Claps F; Antonelli A; Marchioni M; Paksoy N; Erdem S; Derweesh IH
    Eur Urol Open Sci; 2024 May; 63():71-80. PubMed ID: 38572300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors.
    Shimizu T; Miyake M; Nishimura N; Yoshida T; Itami Y; Tachibana A; Omori C; Oda Y; Kohashi M; Tomizawa M; Onishi K; Hori S; Morizawa Y; Dotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K
    Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era.
    Shah NJ; Sura SD; Shinde R; Shi J; Singhal PK; Robert NJ; Vogelzang NJ; Perini RF; Motzer RJ
    Eur Urol Open Sci; 2023 Mar; 49():110-118. PubMed ID: 36874600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
    Savard MF; Wells JC; Graham J; Dudani S; Steinharter JA; McGregor BA; Donskov F; Bjarnason GA; Vaishampayan UN; Hansen AR; Iafolla MAJ; Zanotti G; Huynh L; Chang R; Duh MS; Heng DYC
    Oncologist; 2020 May; 25(5):422-430. PubMed ID: 31971318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.
    Kido K; Hatakeyama S; Numakura K; Tanaka T; Oikawa M; Noro D; Hosogoe S; Narita S; Inoue T; Yoneyama T; Ito H; Nishimura S; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C
    Int J Clin Oncol; 2021 Jan; 26(1):154-162. PubMed ID: 33067647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma?
    Wong ECL; Kapoor A
    Transl Oncol; 2020 Feb; 13(2):241-244. PubMed ID: 31869748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts.
    Bossé D; Xie W; Lin X; Simantov R; Lalani AA; Graham J; Wells JC; Donskov F; Rini B; Beuselinck B; Alva A; Hansen A; Wood L; Soulières D; Kollmannsberger C; Patenaude F; Heng DYC; Choueiri TK; McKay RR
    JCO Glob Oncol; 2020 Feb; 6():293-306. PubMed ID: 32109159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma.
    Jo H; Hong J; Kim H; Kim HR; Kwon GY; Kang KA; Park SY; Kim CK; Park BK; Chung JH; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Park SH
    Front Oncol; 2022; 12():874385. PubMed ID: 35574412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
    Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
    Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
    Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Donskov F; Xie W; Overby A; Wells JC; Fraccon AP; Sacco CS; Porta C; Stukalin I; Lee JL; Koutsoukos K; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim HW; Rathi N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC
    Eur Urol Oncol; 2020 Aug; 3(4):530-539. PubMed ID: 32037304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma.
    Di Nunno V; Mollica V; Schiavina R; Nobili E; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
    Clin Genitourin Cancer; 2020 Apr; 18(2):e83-e90. PubMed ID: 31753738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study.
    Benekli M; Gumus M; Ozkan M; Dane F; Elkiran ET; Cicin I; Sevinc A; Aliustaoglu M; Isikdogan A; Meydan N; Oksuzoglu B; Ozyilkan O; Artac M; Ozdemir F; Kilickap S
    J Oncol Pharm Pract; 2021 Oct; 27(7):1623-1630. PubMed ID: 33050804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.
    Kalra S; Verma J; Atkinson BJ; Matin SF; Wood CG; Karam JA; Lin SH; Satcher RL; Tamboli P; Sircar K; Rao P; Corn PG; Tannir NM; Jonasch E
    Clin Genitourin Cancer; 2017 Jun; 15(3):363-370. PubMed ID: 28216278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastasectomy Improves Overall Survival in Metastatic Renal Cell Carcinoma: A Retrospective Cohort Study.
    Chiou JK; Chang LW; Li JR; Wang SS; Yang CK; Chen CS; Lu K; Cheng CL; Chiu KY; Hung SC
    Anticancer Res; 2023 Jul; 43(7):3193-3201. PubMed ID: 37351976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
    De Lichtenberg TH; Hermann GG; Rørth M; Højer Larsen MJ; Mansourvar Z; Holm ML; Scheike T
    Scand J Urol; 2014 Aug; 48(4):379-86. PubMed ID: 24521185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.